Global Head And Neck Cancer Therapeutics Market Growth Analysis 2024, Forecast To 2033
8 Mar, 2024
The head and neck cancer therapeutics market has experienced rapid expansion, growing from $1.55 billion in 2023 to $1.73 billion in 2024, at a CAGR of 11.7%. This growth is attributed to factors such as tobacco and alcohol consumption, human papillomavirus (HPV) infections, and advancements in treatment modalities. Moving forward, the market is expected to continue its rapid growth, reaching $2.57 billion in 2028, with a CAGR of 10.4%. Factors driving this growth include advances in immunotherapy, precision medicine approaches, and awareness campaigns promoting early diagnosis. Major trends in the forecast period include the expanding role of targeted therapies, adoption of minimally invasive surgical techniques, and the integration of palliative care.
Global Head And Neck Cancer Therapeutics Market Key Driver
The anticipated rise in head and neck cancer cases is set to drive the growth of the head and neck cancer therapeutics market. This form of cancer involves uncontrolled cell growth in the head and neck tissues, necessitating improved diagnosis and treatment options. According to Cancer Research UK, the UK is projected to witness a 3% increase in head and neck cancer incidence and a 12% rise in related deaths between 2023 and 2025. Consequently, the increasing prevalence of head and neck cancer serves as a key driver for the expansion of the head and neck cancer therapeutics market.
Get A Free Sample Of The Global Head And Neck Cancer Therapeutics Market ReportGlobal Head And Neck Cancer Therapeutics Market Segments
The head and neck cancer therapeutics market covered in this report is segmented –
1) Type:Programmed Cell Death (PD) Inhibitors, Microtubule Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors
2) Route Of Administration:Injectable, Oral
3) Distribution Channel:Retail And Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies
4) Application:Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Other Applications
By Geography: The countries covered in the head and neck cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the head and neck cancer therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Head And Neck Cancer Therapeutics Industry Players
Pfizer Inc.; F Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi Aventis LLC; Bristol-Myers-Squibb Company; AstraZeneca PLC; GlaxoSmithKline plc.; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Eisai Co. Ltd.; Sun Pharmaceutical Industries Ltd.; Incyte Corporation; Ono Pharmaceutical Co. Ltd.; Kyowa Kirin Co. Ltd.; Hikma Pharmaceuticals PLC; Clinigen Group plc.; Ligand Pharmaceuticals; Acceleron Pharma Inc.; Taiho Pharmaceutical Co. Ltd.; Boston Biomedical Inc.; AB Science SA.
Get The Full Global Head And Neck Cancer Therapeutics Market Report
Head And Neck Cancer Therapeutics Market Overview
Head and neck cancer therapeutics refer to the various treatment options and approaches to managing and combating head and neck cancers. The head and neck cancer therapeutics can benefit from precision of intensity modulated proton therapy. It also includes efficient therapies such as, surgery, radiation therapy, chemotherapy, certain medications, and immunotherapy.